Autolus Therapeutics (AUTL) to Release Quarterly Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) is anticipated to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $2.98 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Autolus Therapeutics Price Performance

NASDAQ AUTL opened at $1.82 on Tuesday. The company has a fifty day moving average of $2.07 and a two-hundred day moving average of $2.96. The company has a market capitalization of $484.29 million, a PE ratio of -1.50 and a beta of 2.07. Autolus Therapeutics has a 1 year low of $1.68 and a 1 year high of $6.63.

Analyst Ratings Changes

A number of brokerages recently issued reports on AUTL. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics currently has an average rating of “Buy” and a consensus price target of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.